(-)-7′-isothiocyanato-11-hydroxy-1′,1-′dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor

被引:78
作者
Picone, RP
Khanolkar, AD
Xu, W
Ayotte, LA
Thakur, GA
Hurst, DP
Abood, ME
Reggio, PH
Fournier, DJ
Makriyannis, A
机构
[1] Univ Connecticut, Ctr Drug Discovery, Storrs, CT USA
[2] Univ Connecticut, Dept Pharmaceut Sci, Storrs, CT USA
[3] Univ Connecticut, Dept Cell & Mol Biol, Storrs, CT USA
[4] Univ N Carolina, Dept Chem & Biochem, Greensboro, NC 27412 USA
[5] Calif Pacific Med Ctr, Forbes Norris Amyotroph Lateral Sclerosis, Muscular Dystrophy Assoc, Res Ctr, San Francisco, CA 94115 USA
关键词
D O I
10.1124/mol.105.014407
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CB1 cannabinoid receptor has been shown to play important physiological roles in the central nervous system, as well as peripherally, and is a target for development of therapeutic medications. To gain insight on the ligand binding site(s) and structural features of activation, we designed and synthesized (-)-7'-isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol(AM841), a classical cannabinoid affinity label that incorporates an isothiocyanate substituent as an electrophilic reactive group capable of interacting irreversibly with a suitably located and properly oriented nucleophilic amino acid residue at or near the binding site. To obtain evidence for the site of covalent attachment of AM841, C6.47, identified in part by interactive ligand docking, was mutated to serine, alanine, and leucine to reduce or eliminate the nucleophilic character. Wild-type (WT) and mutant CB1 receptors were evaluated for their abilities to recognize a series of cannabinergic ligands. Each bound comparably to WT, excluding C6.47L, which displayed a reduced affinity for H-3-labeled (1R, 3R, 4R)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4(3-hydroxypropyl) cyclohexan-1-ol(CP55940),AM841, 11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM4056), and (-)-7'-bromo-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol(AM4043) and an improvement in affinity for (-)-trans-Delta(9)-tetrahydrocannabinol (Delta(9)-THC). The affinity of H-3-labeled [2,3dihydro- 5-methyl-3-[(4-morpholinyl)methyl]pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]( naphthyl) methanone (WIN55212-2) was unchanged across all mutants. It is noteworthy that AM841 was shown to bind irreversibly to WT CB1 but exhibited no covalent attachment with the mutants and behaved as an agonist suggesting irreversible attachment to C6.47 maintains CB1 in its active state. The evidence presented identifies C6.47 as the site of covalent bond formation with AM841 and combined with the binding data fully supports the molecular modeling. These studies present the first report of tandem applications of affinity labeling, site-directed mutagenesis, and interactive ligand docking for CB1.
引用
收藏
页码:1623 / 1635
页数:13
相关论文
共 45 条
  • [11] FARRENS DL, 1996, SCIENCE, V24, P768
  • [12] Cysteine residues in the human cannabinoid receptor: Only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding
    Fay, JF
    Dunham, TD
    Farrens, DL
    [J]. BIOCHEMISTRY, 2005, 44 (24) : 8757 - 8769
  • [13] Agonists induce conformational changes in transmembrane domains III and VI of the beta(2) adrenoceptor
    Gether, U
    Lin, S
    Ghanouni, P
    Ballesteros, JA
    Weinstein, H
    Kobilka, BK
    [J]. EMBO JOURNAL, 1997, 16 (22) : 6737 - 6747
  • [14] Agonist-induced conformational changes in the G-protein-coupling domain of the β2 adrenergic receptor
    Ghanouni, P
    Steenhuis, JJ
    Farrens, DL
    Kobilka, BK
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (11) : 5997 - 6002
  • [15] (-)-11-HYDROXY-7'-ISOTHIOCYANATO-1',1'DIMETHYLHEPTYL-DELTA(8)-THC - A NOVEL, HIGH-AFFINITY IRREVERSIBLE PROBE FOR THE CANNABINOID RECEPTOR IN THE BRAIN
    GUO, Y
    ABADJI, V
    MORSE, KL
    FOURNIER, DJ
    LI, XY
    MAKRIYANNIS, A
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (23) : 3867 - 3870
  • [16] International Union of Pharmacology. XXVII. Classification of cannabinoid receptors
    Howlett, AC
    Barth, F
    Bonner, TI
    Cabral, G
    Casellas, P
    Devane, WA
    Felder, CC
    Herkenham, M
    Mackie, K
    Martin, BR
    Mechoulam, R
    Pertwee, RG
    [J]. PHARMACOLOGICAL REVIEWS, 2002, 54 (02) : 161 - 202
  • [17] Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor
    Huffman, JW
    Yu, S
    Showalter, V
    Abood, ME
    Wiley, JL
    Compton, DR
    Martin, BR
    Bramblett, RD
    Reggio, PH
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) : 3875 - 3877
  • [18] The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm
    Hulme, EC
    Lu, ZL
    Ward, SDC
    Allman, K
    Curtis, CAM
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 375 (1-3) : 247 - 260
  • [19] N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor
    Hurst, DP
    Lynch, DL
    Barnett-Norris, J
    Hyatt, SM
    Seltzman, HH
    Zhong, M
    Song, ZH
    Nie, JJ
    Lewis, D
    Reggio, PH
    [J]. MOLECULAR PHARMACOLOGY, 2002, 62 (06) : 1274 - 1287
  • [20] Constitutive activation of the beta(2) adrenergic receptor alters the orientation of its sixth membrane-spanning segment
    Javitch, JA
    Fu, DY
    Liapakis, G
    Chen, JY
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (30) : 18546 - 18549